PTC Research Development from 2010 to 2026
| PTCT Stock | USD 67.49 4.67 7.43% |
Research Development | First Reported 2004-12-31 | Previous Quarter 100.2 M | Current Value 133.1 M | Quarterly Volatility 58.4 M |
Review PTC Therapeutics financial statements over time to add context on performance and capital structure. Track Interest Expense of 159.8 M, Total Revenue of 1.8 B or Research Development of 284.3 M and ratios such as Price To Sales Ratio of 3.32, Dividend Yield of 0.0 or Days Sales Outstanding of 50.7 to align performance context with PTC Therapeutics Valuation and Volatility.
PTC | Research Development | Build AI portfolio with PTC Stock |
The evolution of Research Development for PTC Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how PTC Therapeutics compares to historical norms and industry peers.
Latest PTC Therapeutics' Research Development Growth Pattern
Below is the plot of the Research Development of PTC Therapeutics over the last few years. It is PTC Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PTC Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
PTC Research Development Regression Statistics
| Arithmetic Mean | 273,901,150 | |
| Geometric Mean | 175,166,410 | |
| Coefficient Of Variation | 83.72 | |
| Mean Deviation | 199,184,872 | |
| Median | 171,984,000 | |
| Standard Deviation | 229,303,757 | |
| Sample Variance | 52580.2T | |
| Range | 646.5M | |
| R-Value | 0.82 | |
| Mean Square Error | 17929T | |
| R-Squared | 0.68 | |
| Significance | 0.000046 | |
| Slope | 37,454,160 | |
| Total Sum of Squares | 841283.4T |
PTC Research Development History
PTC Therapeutics Net Worth Estimate
PTC Therapeutics is a large-cap equity in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care categories. Peer comparison highlights relative pricing efficiency. We evaluate PTC Therapeutics through the lens of long-term portfolio construction and diversification efficiency.
Methodology
Unless otherwise specified, financial data for PTC Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. PTC (USA Stocks:PTCT) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions Valuation estimates and intrinsic-value models use inputs from public financial disclosures and may not represent market consensus.
Assumptions
The dataset for PTC Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.Analyst Sources
PTC Therapeutics is covered by 14 analysts. 7 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Stifel, Barclays, Morgan Stanley, Wells Fargo Securities, Evercore ISI, BMO Capital Markets, HSBC Global Research, Jefferies, among others. Updates may occur throughout the day.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for PTC Stock Analysis
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |